Theralase Release’s 3Q2023 Interim Financial Statements
TORONTO, ON / ACCESSWIRE / November 29, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
Disability
Nalu Medical, Inc., Announces Positive Results of US Spinal Cord Stimulation Clinical Study in Pain Physician Journal
CARLSBAD, Calif.--(BUSINESS WIRE)--Nalu Medical, Inc (“Nalu”) is a Carlsbad, California-based company that has successfully miniaturized neurostimulation implants for the management...
Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients
Health Canada authorized the Company’s protocol amendment that expands eligibility to include patients aged 12 and older with stage four...
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights...
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy
MELBOURNE, Australia and SAN FRANCISCO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
Scilex Holding Company Announces Market Research Results with Neurologists, Headache Specialists, and Primary Care Physicians Demonstrating Potential High Unmet Needs In Treating Acute Migraine Targeted By ELYXYB® with Potential Advantages Compared to Calcitonin Gene-Related Peptide (CGRP) Products and Triptan Therapy
Exhibit A Exhibit A Exhibit B Exhibit B Exhibit C Exhibit C Migraines affect over 37 million Americans, according to...
Louisiana Insurer Expands Deep TMS™ Access for 1.9 Million Covered Lives
BURLINGTON, Mass. and JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Announced positive full 24-week data from the...
Novo Nordisk A/S: Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine
Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events (MACE) with risk reductions demonstrated...
Elucid Raises $80 Million in Series C Round Led by Elevage Medical Technologies
Investment will drive commercialization and expansion of AI-powered non-invasive diagnostic tools to help evaluate cardiovascular riskBOSTON--(BUSINESS WIRE)--Elucid, a leading medical...
Mayor Bowser Joins Trusted Medical to Celebrate DC Clinic and Expanded Services
WASHINGTON, DC / ACCESSWIRE / November 8, 2023 / Mayor Muriel Bowser joined the Trusted Medical team today as we...
New Real-World Data Show TREMFYA® (guselkumab) Was Associated With Clinically Meaningful Improvements in Patient-Reported Outcomes for Adults Living With Active Psoriatic Arthritis
People living with treatment-resistant active psoriatic arthritis reported meaningful improvements in pain, physical function and fatigue on guselkumab through six...
Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting
− The Study Met Its Primary Endpoint with 53.3% and 54.2% of Patients Treated With TAK-279 (15 mg and 30...
Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates
Third quarter 2023 revenues of $1.8 billion; Company expects 2023 revenues of at least $6 billionSpikevax U.S. market share to...
ThinkSono Joins Butterfly Garden to Deploy ThinkSono AI on Butterfly’s Imaging Platform
ThinkSono enters Butterfly Garden, leveraging Butterfly Network's software development kit (SDK) to build and deploy ThinkSono AI that will be...
Philips and World Stroke Organization partner to improve access to high-quality stroke care
A stroke patient rushed into the hospital October 10, 2023 Two-year partnership focused on advocacy, education, and raising awareness of...
Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress
“VANQUISH” Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH)...
Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
DALLAS, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on...
New Safety Data Suggests SPRAVATO®▼ (Esketamine Nasal Spray) is More Tolerable and Effective Compared to Quetiapine Extended-Release (XR) in Adults with Treatment-resistant Major Depressive Disorder
Beerse, Belgium, Oct. 08, 2023 (GLOBE NEWSWIRE) -- The new safety data is from the ESCAPE-TRD Phase 3b study1Additional findings...
New Safety Data Suggests SPRAVATO®▼ (Esketamine Nasal Spray) is More Tolerable and Effective Compared to Quetiapine Extended-Release (XR) in Adults with Treatment-resistant Major Depressive Disorder
Beerse, Belgium, Oct. 08, 2023 (GLOBE NEWSWIRE) -- The new safety data is from the ESCAPE-TRD Phase 3b study1Additional findings...